Mesenchymal Stromal Cell Therapy in Cardiovascular Disease: Reconsidering Clinical Inconsistency Through the Mechanism–Endpoint Relationship

Luca Bonanni; Nicola Ferri

doi:10.31083/rcm52521

Vollständiger Abstract

Worum geht es in dieser Arbeit?

Mesenchymal stromal cell (MSC) therapy has been investigated for more than two decades as a regenerative approach in cardiovascular disease. Preclinical studies have shown reproducible biological activity; however, clinical translation has been less convincing. Trials in acute myocardial infarction (AMI) and heart failure (HF) have established feasibility and an acceptable safety profile; however, effects on functional and imaging parameters remain modest, and a consistent impact on mortality, hospitalization, and other hard clinical outcomes has not been demonstrated.

Bibliografischer Nachweis

Publikationsdaten

Autor:innen: Luca Bonanni, Nicola Ferri
Quelle: Reviews in Cardiovascular Medicine
Publikation: 2026-01-01
Band / Ausgabe: Nicht angegeben
Seiten: Nicht angegeben
ISSN / ISBN: 1530-6550, 2153-8174
Zitationen: 0 laut Crossref
Referenzen: 0 hinterlegt

Zitieren

Zitierfähiger Nachweis

Luca Bonanni, Nicola Ferri (2026). Mesenchymal Stromal Cell Therapy in Cardiovascular Disease: Reconsidering Clinical Inconsistency Through the Mechanism–Endpoint Relationship. Reviews in Cardiovascular Medicine. https://doi.org/10.31083/rcm52521

RIS BibTeX CSL-JSON

Kontext

Themen, Förderung und Nutzung

Lizenzhinweise: Lizenz 1